Inactivation reagent for enveloped viruses and pathogenic bacteria and application of inactivation reagent

Abstract

The invention relates to an inactivation reagent for enveloped viruses and pathogenic bacteria and application of the inactivation reagent. The inactivation reagent provided by the invention is mainly composed of low-carbon alcohol, an ester compound, a surfactant and a buffer solution; the volume percentage content of the low-carbon alcohol is 1%-10%; the molar concentration of the ester compound is 0.5 mol / L-1. 5mol / L; the volume percentage content of the surfactant is 0.5%-5%; and preferably, the inactivation reagent further comprises a nuclease inhibitor. The reagent achieves an inactivation effect by destroying a lipid layer of enveloped viruses and the like, the action time is short, the inactivation effect can be achieved only in 1 h; meanwhile, the reagent can also be used for inactivation of pathogenic bacteria (corynebacterium diphtheriae, legionella pneumophila and the like), nucleic acid and antigen detection of pathogens cannot be affected, clinical diversified detection can be met; and therefore, the method has a good application value.

Description

technical field [0001] The invention belongs to the technical field of biomedicine, and in particular relates to an inactivation reagent for enveloped viruses and pathogenic bacteria and an application thereof. Background technique [0002] Common clinical respiratory pathogens: Gram-positive Streptococcus pneumoniae, Staphylococcus aureus, Streptococcus pyogenes, Mycobacterium tuberculosis, Nocardia, Corynebacterium diphtheriae, Bacillus anthracis, etc.; Gram-negative bacteria catarrhalis bacteria, Haemophilus influenzae, Neisseria meningitidis, Klebsiella pneumoniae, Pseudomonas bacteria, Legionella pneumophila and Bordetella pertussis, etc. It has been proven that 95% of acute upper respiratory diseases and most of lower respiratory diseases are caused by pathogens other than bacteria, among which respiratory viruses are the most common. [0003] Common clinical respiratory viruses include: influenza virus A, influenza virus B, parainfluenza virus 1, 2, 3, respiratory sy...

AI Technical Summary

Problems solved by technology

This creates a new technical problem: inactivation of proteins or nucleic acids in a manner that prevents multiplex detection in clinical samples

The publication number is CN102224237A, although it is mentioned that β propiolactone can be used to inactivate bacteria, but β propiolactone acts on nucleic acid and affects nucleic acid detection

Therefore, the existing technology either affects nucleic acid detection or antigen detection, or has a long acting time (more than 4 hours), which limits the diversified detection of clinical samples

Images